Currently, we do not serve Arkansas, Connecticut, and New Mexico
SELECT Cardiovascular Outcomes Data Not Just a Weight Loss Drug The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in overweight and obese patients with established CVD
[1] [3] However, some patients report experiencing swelling or fluid retention whilst taking this medication, prompting questions about a potential connection
40 Oral semaglutide or SNAC alone did not appear to alter the exposure of lisinopril, warfarin, or digoxin
See Our Reviews and Connect With Us Google My Business Review : See what our clients are saying about their experience with IV Better
Eli Lilly) in August 2025, and the subsequent stockpiling of medicines, demonstrates the importance of public education and good clinical support being available for patients by their providers 1